Patents by Inventor Ralf Guenther
Ralf Guenther has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11813307Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: GrantFiled: June 4, 2018Date of Patent: November 14, 2023Assignees: MERCK PATENT GMBH, ABLYNX NVInventors: Soren Steffensen, Gerald Beste, Hans Guehring, Lars Toleikis, Christoph Ladel, Sven Lindemann, Roland Kellner, Ralf Guenther
-
Publication number: 20220289860Abstract: The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: ApplicationFiled: January 19, 2022Publication date: September 15, 2022Inventors: Marie-Ange Buyse, Guy Hermans, Sven Lindemann, Hans Guehring, Ralf Guenther, Roland Kellner
-
Patent number: 11261260Abstract: The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: GrantFiled: June 4, 2018Date of Patent: March 1, 2022Assignees: Merck Patent GmbH, ABLYNX NVInventors: Marie-Ange Buyse, Guy Hermans, Sven Lindemann, Hans Guehring, Ralf Guenther, Roland Kellner
-
Publication number: 20210008160Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: ApplicationFiled: June 4, 2018Publication date: January 14, 2021Applicants: Merck Patent GmbH, ABLYNX NVInventors: Soren STEFFENSEN, Gerald BESTE, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL, Sven LINDEMANN, Roland KELLNER, Ralf GUENTHER
-
Publication number: 20200317802Abstract: The present invention relates to immunoglobulins that bind ADAMTSS and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.Type: ApplicationFiled: June 4, 2018Publication date: October 8, 2020Applicants: Merck Patent GmbH, ABLYNX NVInventors: Marie-Ange BUYSE, Guy HERMANS, Sven LINDEMANN, Hans GUEHRING, Ralf GUENTHER, Roland KELLNER
-
Patent number: 10676733Abstract: The present invention provides methods for the non-covalent surface display of proteins of interest (POI), in particular for Fc-domain containing proteins such as antibodies. The inventive method may be used to screen and select proteins of interest of a desired phenotype. The present invention further discloses polynucleotides and proteins and methods of producing the same, which may be used in carrying out the inventive method.Type: GrantFiled: October 27, 2015Date of Patent: June 9, 2020Assignee: Merck Patent GmbHInventors: Laura Rhiel, Stefan Becker, Ralf Guenther, Bjoern Hock, Daniel Helman, Mira Toister-Achituv, Simon Krah
-
Patent number: 10183994Abstract: The invention relates to anti-TNF? antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNF? antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.Type: GrantFiled: June 26, 2015Date of Patent: January 22, 2019Assignee: Merck Patent GmbHInventors: Ralf Guenther, Stefan Becker, Laura Rhiel, Bjoern Hock, Christian Schroeter
-
Publication number: 20180298374Abstract: The present invention provides methods for the non-covalent surface display of proteins of interest (POI), in particular for Fc-domain containing proteins such as antibodies. The inventive method may be used to screen and select proteins of interest of a desired phenotype. The present invention further discloses polynucleotides and proteins and methods of producing the same, which may be used in carrying out the inventive method.Type: ApplicationFiled: October 27, 2015Publication date: October 18, 2018Applicant: Merck Patent GmbHInventors: Laura Rhiel, Stefan Becker, Ralf Guenther, Bjoern Hock, Daniel Helman, Mira Toister-Achituv, Simon Krah
-
Publication number: 20170226199Abstract: The invention relates to anti-TNFa antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNFa antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.Type: ApplicationFiled: June 26, 2015Publication date: August 10, 2017Applicant: Merck Patent GmbHInventors: Ralf GUENTHER, Stefan BECKER, Laura RHIEL, Bjoern HOCK, Christian SCHROETER
-
Patent number: 8969318Abstract: Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.Type: GrantFiled: December 12, 2011Date of Patent: March 3, 2015Assignee: Merck Patent GmbHInventors: Lars Toleikis, Ralf Guenther, Bjoern Hock, Achim Doerner
-
Publication number: 20140039042Abstract: Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.Type: ApplicationFiled: December 12, 2011Publication date: February 6, 2014Applicant: MERCK PATENT GMBHInventors: Lars Toleikis, Ralf Guenther, Bjoern Hock, Achim Doerner
-
Publication number: 20130289259Abstract: Magnetic Resonance Imaging based on 19F instead of 1H opens up new diagnostic possibilities. The 19F nucleus has a high gyromagnetic ratio (40 MHz/T) and a natural isotopic abundance ratio of 100%. In the human body, 19F containing structures are exclusively present in the form of solid salts, e.g. teeth and bones. The J2 relaxation times of the endogenous 19F atoms are extremely short and the MR signal is hardly detectable. The lack of endogenous 19F-based structures with relatively high transverse relaxation times assures a very low background MR signal. Therefore, exogenous 19F-based MRI contrast agents allow for “hot spot” imaging in a way similar to other techniques such as PET. As a useful extension of its diagnostic use, MRI is also proposed for the monitoring of the delivery of bio-active agents such as therapeutic or diagnostic agents.Type: ApplicationFiled: December 12, 2011Publication date: October 31, 2013Applicant: MERCK PATENT GMBHInventors: Ralf Guenther, Bjoern Hock, Simon Goodman, Birgit Piater
-
Patent number: 6888827Abstract: The invention relates to a communication system which operates in the asynchronous transfer mode (ATM) and which comprises several nodes which form a network and are partly coupled to one another and to terminals, and which each comprise a switch and a control software at least for controlling the relevant coupling field and for the signaling. At least one object of the control software contains detection points in certain states. An object for event handling of the control software is provided for further processing when a detection point is reached. The object for event handling receives data via a special channel from at least one terminal or from another node.Type: GrantFiled: June 26, 1998Date of Patent: May 3, 2005Assignee: Koninklijke Philips Electronics N.V.Inventors: Jesus-Manuel Duque-Antón, Ralf Günther, Thomas Meuser, Josef Wasel, Raschid Karabek
-
Patent number: 6569469Abstract: The invention relates to a method for producing an antioxidatively active extract which can be used in particular for stabilizing foodstuffs and cosmetic agents. According to the method, non-enzymatically browned grain germs, or a mixture containing non-enzymatically browned grain germs, is/are extracted using a solvent or solvent mixture (e.g. ethanol or an ethanolic mixture) having an ETN value ranging from 0.6 to 0.8, and the extracting agent is then optionally separated off. The invention also relates to a method for stabilizing unbrowned grain germs in which these unbrowned grain germs are mixed with non-enzymatically browned grain germs.Type: GrantFiled: March 14, 2001Date of Patent: May 27, 2003Assignee: Universität HannoverInventors: Yasser El Saharty, Ulrich Krings, Ralf Günther Berger
-
Patent number: 6022107Abstract: The purpose of the invention is to determine the topography of retinal reactions with high effectiveness and great certainty. In accordance with the invention, the problem is solved by generating a light-emitting image consisting of surface segments on a surface placed before the eye, and using complete extended m sequences, to brighten and darken the surface segments in each time interval. From the eye reaction signal, with the aid of the cross-correlation function, the reaction functions of the segments are calculated in each time interval, and the quality of the results is evaluated by forming some functions for each time interval. Only reaction signals evaluated as good are added up for the total result. The reaction signal of the eye is monitored for staying within limit values, and when errors are recognized, the m sequences are set back by a number of steps which can be preset, recognized errors in the reaction signal are replaced by the repetition.Type: GrantFiled: April 6, 1999Date of Patent: February 8, 2000Assignee: Cindatec Ingenieurtechnische Dienste GmbHInventors: Ernst Kutschbach, Uwe Held, Uwe Hoch, Ralf Guenther, Manfred Stasche, Albrecht Hinkel